Vivita Technologies
Organisation
People
Sources: reporter.nih.gov
Grants and prizes
National Heart, Lung, and Blood Institute
R43, Unfixed, xenogeneic extracellular matrix for crimp damage-resistant and regenerative transcatheter heart valve prostheses, R43HL180206, US$496.3k, 2025–2027, 30 Jul 2025
National Heart, Lung, and Blood Institute
R44, Immune-compatible, unfixed, xenogeneic extracellular matrix for heart valve prostheses, R44HL164140, US$744.2k, 2022–2025, 22 May 2023
Sources: reporter.nih.gov